Moelis & Company (MC) EPS Estimated At $0.64; Casi Pharmaceuticals (CASI) Shorts Up By 19.72%

January 14, 2018 - By Michael Collier

Casi Pharmaceuticals Incorporated (NASDAQ:CASI) had an increase of 19.72% in short interest. CASI’s SI was 745,400 shares in January as released by FINRA. Its up 19.72% from 622,600 shares previously. With 458,200 avg volume, 2 days are for Casi Pharmaceuticals Incorporated (NASDAQ:CASI)’s short sellers to cover CASI’s short positions. The SI to Casi Pharmaceuticals Incorporated’s float is 2.06%. The stock decreased 0.79% or $0.03 during the last trading session, reaching $3.75. About 281,022 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has declined 17.65% since January 14, 2017 and is downtrending. It has underperformed by 34.35% the S&P500.

Analysts expect Moelis & Company (NYSE:MC) to report $0.64 EPS on February, 14.They anticipate $0.02 EPS change or 3.03% from last quarter’s $0.66 EPS. MC’s profit would be $35.79M giving it 19.63 P/E if the $0.64 EPS is correct. After having $0.57 EPS previously, Moelis & Company’s analysts see 12.28% EPS growth. The stock increased 1.31% or $0.65 during the last trading session, reaching $50.25. About 184,528 shares traded. Moelis & Company (NYSE:MC) has risen 40.93% since January 14, 2017 and is uptrending. It has outperformed by 24.23% the S&P500.




Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.53, from 1.67 in 2017Q2. It fall, as 3 investors sold CASI Pharmaceuticals, Inc. shares while 4 reduced holdings. 4 funds opened positions while 4 raised stakes. 2.39 million shares or 4.17% more from 2.29 million shares in 2017Q2 were reported. Vanguard Group has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 358,972 shares. Savings Bank Of America De stated it has 1,144 shares or 0% of all its holdings. Ontario – Canada-based Royal Fincl Bank Of Canada has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields Ltd stated it has 0.29% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Howland Capital Management Lc reported 24,139 shares or 0% of all its holdings. Blackrock reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Virtu Financial Limited Liability Company reported 40,790 shares. Deutsche Commercial Bank Ag reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Wellington Shields Cap Mgmt Limited Liability Company holds 0.17% or 725,348 shares in its portfolio. Manatuck Hill Prtnrs Ltd Liability holds 0.01% or 15,090 shares in its portfolio. Illinois-based Northern Tru Corp has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris & Communications Ca invested in 0% or 10,002 shares. The California-based California Employees Retirement Systems has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Next Fincl Gru invested in 2 shares or 0% of the stock. Renaissance Techs Ltd Liability holds 112,900 shares or 0% of its portfolio.

Among 2 analysts covering CASI Pharmaceuticals Inc (NASDAQ:CASI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. CASI Pharmaceuticals Inc had 4 analyst reports since October 29, 2015 according to SRatingsIntel. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has “Buy” rating given on Monday, August 14 by Maxim Group. On Thursday, September 22 the stock rating was initiated by Maxim Group with “Buy”. The stock of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has “Buy” rating given on Thursday, October 29 by H.C. Wainwright.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $244.00 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The companyÂ’s late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkinÂ’s lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkinÂ’s lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

Moelis & Company provides strategic and financial advisory services in the United States and internationally. The company has market cap of $2.81 billion. The firm advises clients in the areas of mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It has a 24.14 P/E ratio. Moelis & Company offers its services to public multinational firms, governments, financial sponsors, middle market private companies, and individual entrepreneurs.

Among 13 analysts covering Moelis & Co (NYSE:MC), 6 have Buy rating, 0 Sell and 7 Hold. Therefore 46% are positive. Moelis & Co had 28 analyst reports since August 11, 2015 according to SRatingsIntel. The stock has “Hold” rating by Keefe Bruyette & Woods on Wednesday, January 10. The stock of Moelis & Company (NYSE:MC) earned “Overweight” rating by Morgan Stanley on Thursday, October 26. The firm has “Market Perform” rating by Wood given on Tuesday, August 11. The firm earned “Hold” rating on Thursday, December 21 by Keefe Bruyette & Woods. The stock of Moelis & Company (NYSE:MC) has “Buy” rating given on Tuesday, July 25 by Bank of America. Morgan Stanley maintained the shares of MC in report on Tuesday, July 25 with “Overweight” rating. Buckingham Research initiated Moelis & Company (NYSE:MC) on Monday, December 21 with “Neutral” rating. On Wednesday, January 13 the stock rating was upgraded by Buckingham Research to “Buy”. The stock of Moelis & Company (NYSE:MC) has “Mkt Perform” rating given on Friday, May 5 by Keefe Bruyette & Woods. On Thursday, August 4 the stock rating was maintained by UBS with “Neutral”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: